Comparative Pharmacology
Head-to-head clinical analysis: PULMICORT FLEXHALER versus QVAR REDIHALER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PULMICORT FLEXHALER versus QVAR REDIHALER.
PULMICORT FLEXHALER vs QVAR REDIHALER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Budesonide is a corticosteroid with potent anti-inflammatory effects. It inhibits multiple inflammatory cell types and mediators such as cytokines, chemokines, and adhesion molecules, reducing airway hyperresponsiveness and inflammation.
Beclomethasone dipropionate is a prodrug that is hydrolyzed by esterases to the active metabolite beclomethasone-17-monopropionate (17-BMP). 17-BMP is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to modulation of gene expression involved in inflammatory pathways, including inhibition of pro-inflammatory cytokines, reduction of eosinophil survival and migration, and suppression of mast cell mediators.
Inhalation: 1-2 inhalations (90-180 mcg) twice daily; maximum 720 mcg twice daily.
Inhalation: 40-80 mcg twice daily; maximum 320 mcg twice daily.
None Documented
None Documented
Terminal half-life: 2.0-3.5 hours (mean 2.5 h) in adults after inhalation. Clinically, duration of effect may persist beyond pharmacokinetic half-life due to receptor binding.
1.5-2.0 hours (terminal half-life) after inhalation; supports twice-daily dosing.
Renal: ~60% as metabolites, fecal: ~40% as metabolites. Less than 10% unchanged in urine.
Primarily hepatic metabolism via CYP3A4; metabolites are excreted in feces (~64%) and urine (~12%).
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid